Which blood thinner combo best prevents a second stroke?
NCT ID NCT06591377
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two antiplatelet drug combinations—ticagrelor plus aspirin versus cilostazol plus aspirin—given within 24 hours of a minor stroke or TIA. The goal is to see which combination better prevents new strokes over 90 days while keeping bleeding complications low. About 900 adults aged 18-75 with a first-time large-vessel minor stroke or TIA are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ticagrelor and cilostazol, each combined with aspirin
What this could lead to
If successful, this could identify a better dual-antiplatelet regimen to reduce the risk of another stroke after a minor stroke or TIA.
What could go wrong
This is a single-center trial, and results may not apply to all populations. Both drug combinations increase bleeding risk, which could outweigh benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
El-sahel teaching hospital
RECRUITINGCairo, 22514, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kafr Elsheikh University Hospital
RECRUITINGKafr ash Shaykh, 33511, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact